Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 166 AL 180

Rehabilitating a brain with Alzheimer's: a proposal

Aranda-Abreu GE, Hernández-Aguilar ME, Manzo Denes J, García Hernández LI, Herrera Rivero M.

Clin Interv Aging. 2011;6:53-9. doi: 10.2147/CIA.S14008. Epub 2011 Feb 22.

Silencing of CDK5 as potential therapy for Alzheimer's disease

López-Tobón A, Castro-Álvarez JF, Piedrahita D, Boudreau RL, Gallego-Gómez JC, Cardona-Gómez GP.

Rev Neurosci. 2011;22(2):143-52. doi: 10.1515/RNS.2011.015.

Platelets, inflammation and tissue regeneration

Nurden AT.

Thromb Haemost. 2011 May;105 Suppl 1:S13-33. doi: 10.1160/THS10-11-0720. Epub 2011 Apr 11.

Epigenetic mechanisms in Alzheimer's disease

Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J.

Neurobiol Aging. 2011 Jul;32(7):1161-80. doi: 10.1016/j.neurobiolaging.2010.08.017. Epub 2011 Apr 11.

Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Schneider LS, Dagerman KS, Higgins JP, McShane R.

Arch Neurol. 2011 Aug;68(8):991-8. doi: 10.1001/archneurol.2011.69. Epub 2011 Apr 11.

Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations'

Bertram L.

Curr Neurol Neurosci Rep. 2011 Jun;11(3):246-53. doi: 10.1007/s11910-011-0193-z.

[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease]

Delrieu J, Piau A, Vellas B.

Rev Med Interne. 2011 Jun;32 Suppl 1:S22-5. doi: 10.1016/j.revmed.2011.03.005. Epub 2011 Apr 13.

Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease

Nie Q, Du XG, Geng MY.

Acta Pharmacol Sin. 2011 May;32(5):545-51. doi: 10.1038/aps.2011.14. Epub 2011 Apr 18.

Assessing family caregiver skill in managing behavioral symptoms of Alzheimer's disease

Farran CJ, Fogg LG, McCann JJ, Etkin C, Dong X, Barnes LL.

Aging Ment Health. 2011 May;15(4):510-21. doi: 10.1080/13607863.2010.536140.

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A.

Expert Opin Biol Ther. 2011 Jun;11(6):679-86. doi: 10.1517/14712598.2011.579099. Epub 2011 Apr 19.

A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease

Antonell A, Balasa M, Oliva R, Lladó A, Bosch B, Fabregat N, Fortea J, Molinuevo JL, Sánchez-Valle R.

Neurosci Lett. 2011 May 27;496(1):40-2. doi: 10.1016/j.neulet.2011.03.084. Epub 2011 Apr 9.

Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome?

Larner AJ.

Epilepsy Behav. 2011 May;21(1):20-2. doi: 10.1016/j.yebeh.2011.03.022. Epub 2011 Apr 17.

Effects of different learning methods for instrumental activities of daily living in patients with Alzheimer's dementia: a pilot study

Dechamps A, Fasotti L, Jungheim J, Leone E, Dood E, Allioux A, Robert PH, Gervais X, Maubourguet N, Olde Rikkert MG, Kessels RP.

Am J Alzheimers Dis Other Demen. 2011 Jun;26(4):273-81. doi: 10.1177/1533317511404394. Epub 2011 Apr 17.

Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors

Mancini F, De Simone A, Andrisano V.

Anal Bioanal Chem. 2011 Jun;400(7):1979-96. doi: 10.1007/s00216-011-4963-x. Epub 2011 Apr 20.

Solanezumab for Alzheimer's disease

Samadi H, Sultzer D.

Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi: 10.1517/14712598.2011.578573. Epub 2011 Apr 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias